Marie-Eve Brault

Marie-Eve Brault has held various positions in the biotechnology and pharmaceutical industry since 2001. Marie-Eve began their career as an intern at Biolactis in 2001, followed by an internship at PerkinElmer in 2003, where they optimized a high-throughput assay to detect insulin using AlphaScreen technology. From 2007-2011, they were a Ph.D. student at McGill University, where they self-initiated a project that identified Dyskeratosis Congenita causing mutations as sumoylation sites. From 2011-2018, they were a Postdoctoral Fellow at Dana-Farber Cancer Institute, where they generated multiple CRISPR/Cas9 CRISPR/eCas9 cell lines, established new technologies and techniques in the lab, and supervised and trained 10 students, graduate students and research technicians. In 2018, they joined Skyhawk Therapeutics as an Associate Director, Oncology Biology and Principal Scientist/Program Manager.

Marie-Eve Brault's education history includes a Postdoctoral Fellowship from Harvard University (2012-2018) in RNA Biology, a Ph.D from McGill University (2006-2010) in Anatomy and Cell Biology, a Master of Sciences from Université Laval (2005-2006) in Cellular and Molecular Biology, and a B.Sc from Université de Sherbrooke (2001-2004) in Biotechnology.